Thiogenesis Therapeutics' MELAS Abstract Accepted for Late-Breaking News Presentation at Mitocon 2026

Core Insights - Thiogenesis Therapeutics, a clinical-stage biotechnology company, announced that an abstract of preliminary results from its Phase 2 clinical trial of TTI-0102 for MELAS has been accepted for presentation at the Mitocon Conference 2026 [1][2] Company Overview - Thiogenesis Therapeutics is focused on developing next-generation sulfur-based prodrugs aimed at treating rare mitochondrial and metabolic diseases [1][9] - The company is publicly traded on the TSX Venture Exchange and OTCQX, with operations based in San Diego, California [9] Clinical Trial Details - The Phase 2 MELAS clinical trial is a randomized, double-blind, placebo-controlled, multi-center study assessing the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of oral TTI-0102 in patients with MELAS [3] - Interim results have shown biological proof-of-concept and biomarker activity supporting TTI-0102's mechanism of action [3] Presentation at Mitocon Conference - The poster titled "Pharmacokinetics and Pharmacodynamics of TTI-0102 in MELAS" will be presented on January 23, summarizing preliminary findings from the Phase 2 MELAS study [2] - The selection for a late-breaking presentation highlights the scientific importance of the data generated in the study [4] Product Information - TTI-0102 is designed to overcome limitations of first-generation thiol therapies, offering improved tolerability and once-daily dosing [8] - The product candidate is being evaluated for multiple indications related to mitochondrial dysfunction and oxidative stress [8] Related Conditions - MELAS is an inherited mitochondrial disorder with an estimated prevalence of approximately 4.1 per 100,000 people worldwide [6] - Leigh syndrome spectrum, another condition being targeted by Thiogenesis, affects an estimated 1 in 40,000 live births and currently has no approved treatments [7]